Uremic toxins: A new focus on an old subject

Seminars in Dialysis

Volumn 18, Issue 3, 2005, Pages 203-211

  Yavuz, Asuman ^a   Tetta, Ciro ^b   Ersoy, F Fevzi ^a   D'Intini, Vincent ^c   Ratanarat, Ranistha ^c   De Cal, Massimo ^c   Bonello, Monica ^c   Bordoni, Valeria ^c   Salvatori, Gabriella ^c   Andrikos, Emilio ^c   Yakupoglu, Gulsen ^a   Levin, Nathan W ^d   Ronco, Claudio ^c,e  

^a AKDENIZ UNIVERSITY   (Turkey)

^b FRESENIUS MEDICAL CARE   (Germany)

^c SAN BORTOLO HOSPITAL   (Italy)

^d BETH ISRAEL MEDICAL CENTER   (United States)

^e San Bartolo Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ADVANCED GLYCATION END PRODUCT; BETA 2 MICROGLOBULIN; CREATININE; CYANOCOBALAMIN; CYTOKINE; FOLIC ACID; GUANIDINE; HIPPURIC ACID; HOMOCYSTEINE; INDICAN; LEPTIN; PARA CRESOL; PHOSPHATE; POLYAMINE DERIVATIVE; PROPIONIC ACID DERIVATIVE; PYRIDOXINE; SPERMINE; TRIHALOMETHANE; UNCLASSIFIED DRUG; UREMIC TOXIN; UROFURAN ACID;

CREATININE BLOOD LEVEL; HEMODIALYSIS; HORMONE BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; KINETICS; MOLECULAR WEIGHT; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; REVIEW; UREA BLOOD LEVEL; UREMIA;

ALBUMINS; HEMODIALYSIS SOLUTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MEMBRANES, ARTIFICIAL; RENAL DIALYSIS; TOXINS, BIOLOGICAL; UREMIA;

EID: 20544445866     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2005.18313.x     Document Type: Review

References (142)

1. Vanholder R, Glorieux G, De Smet R, Lameire N, European Uremic Toxin Work Group (EUTox): New insights in uremic toxins. Kidney Int 63(suppl 84):S6-S10, 2003
2. National Kidney Foundation: NKF-K/DOQI clinical practice guidelines for peritoneal dialysis adequacy: update 2000. Am J Kidney Dis 37(suppl 1):S65-S136, 2001
3. Steinberg EP, Eknoyan G, Levin NW, Eschbach JW, Golper TA, Owen WF, Schwab S: Methods used to evaluate the quality of evidence underlying the National Kidney Foundation-Dialysis Outcomes Quality Initiative clinical practice guidelines: description, findings, and implications. Am J Kidney Dis 36:1-11, 2000
4. Lim J, Gasson C, Kaji DM: Urea inhibits NaK2Cl cotransport in human erythrocytes. J Clin Invest 96:2126-2132, 1995
5. Xiao S, Wagner L, Mahaney J, Baylis C: Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells. Am J Physiol 280:F989-F995, 2001
6. Maddock AL, Westenfelder C: Urea indices the heat shock response in human neuroblastoma cells. J Am Soc Nephrol 7:275-282, 1996
7. Zhang Z, Yang XY, Cohen DM: Urea-associated oxidative stress and Gadd153/CHOP induction. Am J Physiol 276:F786-F793, 1999
8. Johnson WJ, Hagge WW, Wagoner RD, Dinapoli RP, Rosevear JW: Effects of urea loading in patients with far advanced renal failure. Mayo Clin Proc 47:21-29, 1972
9. Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458-482, 1990
10. De Deyn PP, Macdonald RL: Guanidino compounds that are increased in cerebrospinal fluid and brain of uremic patients inhibit GABA and glycine responses on mouse neurons in cell culture. Ann Neurol 28:627-633, 1990
11. D'Hooge R, Pei YQ, Marescau B, De Deyn PP: Convulsive action and toxicity of uremic guanidino compounds: behavioral assessment and relation to brain concentration in adult mice. J Neurol Sci 112:96-105, 1992
12. Weisensee D, Low-Friedrich I, Riehle M, Bereiter-Hahn J, Schoeppe W: In vitro approach to uremic cardiomyopathy. Nephron 65:392-400, 1993
13. Levine S, Saltzman A: Are urea and creatinine uremic toxins in the rat? Ren Fail 23:53-59, 2001
14. D'Hooge R, De Deyn PP, Van de Vijver G, Antoons G, Raes A, Van Bogaert PP: Uraemic guanidino compounds inhibit gamma-aminobutyric acid-evoked whole cell currents in mouse spinal cord neurones. Neurosci Lett 265:83-86, 1999
15. Yokozawa T, Fujitsuka N, Oura H, Akao T, Kobashi K, Ienaga K, Nakamura K, Hattori M: Purification of methylguanidine synthase from the rat kidney. Nephron 63:452-457, 1993
16. Kerr PG, Lo A, Chin M, Atkins RC: Dialyzer performance in the clinic: comparison of six low-flux membranes. Artif Organs 23:817-821, 1999
17. Haas T, Hillion D, Dongradi G: Phosphate kinetics in dialysis patients. Nephrol Dial Transplant 6(suppl 2):108-113, 1991
18. Pohlmeier R, Vienken J: Phosphate removal and hemodialysis conditions. Kidney Int 59:S190-S194, 2001
19. Spalding EM, Chamney PW, Farrington K: Phosphate kinetics during hemodialysis: evidence for biphasic regulation. Kidney Int 61:655-667, 2002
20. Pogglitsch H, Estelberger W, Petek W, Zitta S, Ziak E: Relationship between generation and plasma concentration of anorganic phosphorous. In vivo studies on dialysis patients and in vitro studies on erythrocytes. Int J Artif Organs 12:524-532, 1989
21. Coburn JW, Salusky IB: Control of serum phosphorus in uremia [editorial]. N Engl J Med 320:1140-1142, 1989
22. Llach F: Secondary hyperparathyroidism in renal failure: the trade off hypothesis revisited. Am J Kidney Dis 25:663-679, 1995
23. de Francisco AL, Cobo MA, Setien MA, Rodrigo E, Fresnedo GF, Unzueta MT, Amado JA, Ruiz JC, Arias M, Rodriguez M: Effect of serum phosphate on parathyroid hormone secretion during hemodialysis. Kidney Int 54:2140-2145, 1998
24. Combe C, Aparicio M: Phosphorous and protein restriction and parathyroid function in chronic renal failure. Kidney Int 46:1381-1386, 1994
25. Imanishi Y, Koyama H, Inaba M, Okuno S, Nishizawa Y, Morii H, Otani S: Phosphorus intake regulates intestinal function and polyamine metabolism uremia. Kidney Int 49:499-505, 1996
26. Del Castillo E, Fuenzalida R, Uranga J: Increased glomerular filtration rate and glomerulopressin activity in diabetic dogs. Horm Metab Res 9:46-53, 1977
27. De Deyn P, Marescau B, Lornoy W, Becaus I, Van Leuven I, Van Gorp L, Lowenthal A: Serum guanidino compound levels and the influence of a single hemodialysis in uremic patients undergoing maintenance hemodialysis. Nephron 45:291-295, 1987
28. De Deyn PP, Marescau B, Swartz RD, Hogaerth R, Possemiers I, Lowenthal A: Serum guanidino compound levels and clearances in uremic patients treated with continuous ambulatory peritoneal dialysis. Nephron 54:307-312, 1990
29. De Deyn PP, Marescau B, Swartz RD, Billiouw JM, Becaus I, Lornoy W: Differential removal of guanidinosuccinic acid and creatine by hemodialysis and continuous ambulatory peritoneal dialysis. Nephron 57:369-370, 1991
30. Radtke HW, Rege AB, Lamarche MB, Bartos D, Bartos F, Campbell RA, Fisher JW: Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J Clin Invest 67:1623-1629, 1981
31. Kushner D, Beckman B, Nguyen L, Chen S, Della Santina C, Husserl F, Rice J, Fisher JW: Polyamines in the anemia of end stage renal disease. Kidney Int 39:725-732, 1991
32. Campbell RA: Polyamines and uremia. Adv Exp Med Biol 223:47-54, 1987
33. Stabellini G, Mariani G, Pezzetti F, Calastrini C: Direct inhibitory effect of uremic toxins and polyamines on proliferation of VERO culture cells. Exp Mol Pathol 64:147-155, 1997
34. Cailleux A, Subra JF, Riberi P, Allain P: Uptake of trihalomethanes by patients during hemodialysis. Clin Chim Acta 181:75-80, 1989
35. Landi S, Hanley NM, Warren SH, Pegram RA, Demarini DM: Induction of genetic damage in human lymphocytes and mutations in Salmonella by trihalomethanes: role of red blood cells and GSSTT1-1 polymorphism. Mutagenesis 14:479-482, 1999
36. Melnick RL, Kohn MC, Dunnick JK, Leininger JR: Regenerative hyperplasia is not required for liver tumor induction in female B6C3F1 mice exposed to trihalomethanes. Toxicol Appl Pharmacol 148:137-147, 1998
37. Coffin JC, Ge R, Yang S, Kramer PM, Tao L, Pereira MA: Effect of trihalomethanes on cell proliferation and DNA methylation in female B6C3F1 mouse liver. Toxicol Sci 58:243-252, 2000
38. Waller K, Swan SH, Delorenze G, Hopkins B: Trihalomethanes in drinking water and spontaneous abortion. Epidemiology 9:134-140, 1998
39. Gejyo F, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunitomo T, Kataoka H, Suzuki M, Hirasawa Y, Shirahama T: A new form of amyloid protein associated with chronic hemodialysis was identified as β2 microglobulin. Biochem Biophys Res Commun 129:701-706, 1985
40. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR: Reactive glycosylation end products in diabetic uremia and treatment of renal failure. Lancet 343:1519-1522, 1994
41. Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K, Matsuo H, Omae T, Matsuoka H: Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 94:2158-2161, 1994
42. Sharma K, Considine RV, Michael B, Dunn SR, Weisberg LS, Kurnik BR, Kurnik PB, O'Connor J, Sinha M, Caro JF: Plasma leptin is partly cleared by kidney and is elevated in hemodialysis patients. Kidney Int 51:1980-1985, 1997
43. Deppisch RM, Beck W, Goehl H, Ritz E: Complement components as uremic toxins and their potential role as mediators of microinflammation. Kidney Int Suppl 78:S271-S277, 2001
44. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA: Plasma levels of IL-1β, TNF-α, and their specific inhibitors in undialyzed chronic renal failure, CAPD, and hemodialyzed patients. Kidney Int 45:890-896, 1994
45. Kaizu Y, Kimura M, Yoneyama T, Miyaji K, Hibi I, Kumagai H: Interleukin-6 may mediate malnutrition in chronic dialysis patients. Am J Kidney Dis 31:93-100, 1998
46. Westbrook J, Feng Z, Chen L, Yang H, Berman HM: The protein data bank. Nucleic Acids Res 28:235-242, 2003
47. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R, Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347:2010-2019, 2002
48. Cheung B, Leung R: Elevated plasma levels of human adrenomedullin in cardiovascular, respiratory, hepatic and renal disorders. Clin Sci 92:59-62, 1997
49. Pecoits-Filho R, Lindholm B, Stenvinkel P: The malnutrition, inflammation, and atherosclerosis (MIA) syndrome - the heart of the matter. Nephrol Dial Transplant 17(suppl):28-31, 2002
50. Fung F, Sherrard DJ, Gillen DL, Wong C, Kestenbaum B, Seliger S, Ball A, Stehman-Breen C: Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis 40:307-314, 2002
51. Memoli B, Minutolo R, Bisesti V, Postiglione L, Conti A, Marzano L, Capuano A, Andreucci M, Balletta MM, Guida B, Tetta C, Collaborative Study Group on SMC Membrane: Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am J Kidney Dis 39:266-273, 2002
52. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML: Uremic toxicity: present state of the art. Int J Artif Organs 24:695-725, 2001
53. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N: Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 40:1005-1012, 2000
54. Matsuo K, Ikizler TA, Hoover RL, Nakamoto M, Yasunaga C, Pupim LB, Hakim RM: Transforming growth factor-beta is involved in pathogenesis of dialysis-related amyloidosis. Kidney Int 57:697-708, 2000
55. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW: Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 38:1408-1413, 2000
56. Martola L, Elinder CG, Stenvinkel P: Why do patients with kidney diseases end up with a heart of stone? Disturbances in calcium-phosphate balance and chronic inflammation important causes. Lakartidningen 100:4180-4183, 2003
57. 2-HS-glycoprotein concentration with maternal insulin resistance and anthropometric parameters of neonates in normal pregnancy and gestational diabetes. Eur J Endocrinol 147:243-248, 2002
58. Bone RC, Grodzin CJ, Balk RA: Sepsis: a new pathogenesis of the disease process. Chest 112:235-243, 1997
59. Koch T: Mechanisms of sepsis and SIRS. Kidney Int 53(suppl 64):S66-S69, 1998
60. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E: Serum cytokine levels in septic shock - relation to multiple system organ failure and mortality. Chest 103:565-575, 1993
61. Depner TA: Suppression of tubular anion transport by an inhibitor of serum protein binding in uremia. Kidney Int 20:511-518, 1981
62. McTigue JJ, Henderson SJ, Lindup WE: Excretion of the uremic metabolite 3-carboxy-4-methyl-5-propyl-2-furanpropanaoic acid in human urine. Nephron 55:214-215, 1990
63. Henderson SJ, Lindup WE: Renal organic acid transport: uptake by rat slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia. J Pharmacol Exp Ther 263:54-60, 1992
64. Costigan MG, Callaghan CA, Lindup WE: Hypothesis: is accumulation of a furan dicarboxylic acid (3-carboxy-4-methyl-5-propyl-2-furanpropionic acid) related to the neurologic abnormalities in patients with renal failure? Nephron 73:169-173, 1996
65. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y: Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 74:349-355, 1996
66. Farrell PC, Gotch FA, Peters JH, Berridge BJ Jr, Lam M: Binding of hippurate in normal plasma and in uremic plasma pre- and postdialysis. Nephron 20:40-46, 1978
67. St Peter WL, Lewis MJ, Macres MG: Pain comparison after subcutaneous administration of single-dose formulation versus multidose formulation of epogen on hemodialysis patients. Am J Kidney Dis 32:470-474, 1998
68. Massy ZA: Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end products) for atherogenesis in uremic patients. Nephrol Dial Transplant 15(suppl 5):81-91, 2000
69. van Guldener C, Janssen MJ, Lambert J, ter Wee PM, Jakobs C, Donker AJ, Stehouwer CD: No change in impaired endothelial function after long term folic acid therapy of hyperhomocysteinemia in hemodialysis patients. Nephrol Dial Transplant 13:106-112, 1998
70. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townsend JN: Does folic acid decrease plasma homocysteine levels and improve endothelial function in patients with predialysis renal failure? Circulation 102:871-875, 2000
71. Curtis HC, Mettler M: Study of the intestinal tyrosine metabolism using stable isotopes and gas chromatography-mass spectrometry. J Chromatogr 126:569-580, 1976
72. Thompson DC, Perera K, Fisher R, Brendel K: Cresol isomers: comparison of toxic potency in rat liver slices. Toxicol Appl Pharmacol 125:51-58, 1994
73. Yehuda S, Carasso RL, Mostofsky DI: Essential fatty acid preparation (SR-3) raises the seizure threshold in rats. Eur J Pharmacol 254:193-198, 1994
74. Kitagawa A: Effects of cresols (o-, m-, and p-isomers) on the bioenergetic system in the isolated rat liver mitochondria. Drug Chem Toxicol 24:39-47, 2001
75. Tetta C, Bellomo R, Formica M, Livigni S, Mariano F, Wratten ML, Carraro G, Ronco C: Use of adsorbents in ARF therapy. Contrib Nephrol 137:181-188, 2002
76. Mingrone G, De Smet R, Greco AV, Bertuzzi A, Gandolfi A, Ringoir S, Vanholder R: Serum uremic toxins from patients with chronic renal failure displace the binding of L-tryptophan to human serum albumin. Clin Chim Acta 260:27-34, 1997
77. Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S: Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int 33:996-1004, 1988
78. Vanholder R, Hoefliger N, De Smet R, Ringoir S: Extraction of protein bound ligands from azotemic sera: comparison of 12 deproteinization methods. Kidney Int 41:1707-1712, 1992
79. Stein G, Franke S, Mahiout A, Schneider S, Sperschneider H, Borst S, Vienken J: Influence of dialysis modality on serum AGE levels in end stage renal disease patients. Nephrol Dial Transplant 16:999-1008, 2001
80. Weiss MF, Erhard P, Kader-Attia FA, Wu YC, Deoreo PB, Araki A, Glomb MA, Monnier VM: Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 57:2571-2585, 2000
81. Sarkar S, Kaitwatcharachai C, Levin N: Nitric oxide and hemodialysis. Semin Dial 17:224-228, 2004
82. Locatelli F, Manzoni C: Duration of dialysis sessions: was Hegel right? Nephrol Dial Transplant 14:560-563, 1999
83. Scribner B: Dialysis therapy in the United States: a historical perspective. Home Hemodial Int 3:9-13, 1999
84. Reynolds JT, Homel P, Cantey L, Evans E, Harding P, Gotch F, Wuerth D, Finkelstein S, Levin N, Kliger A, Simon DB, Finkelstein FO: A one-year prospective trial of short daily hemodialysis (SDHD): clinical parameters [abstract]. J Am Soc Nephrol 13:60A, 2002
85. Fagugli RM, De Smet R, Buoncristiani U, Lameire N, Vanholder R: Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 40:339-347, 2002
86. 2- microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant 15:58-64, 2002
87. Zimmerman DL, Swedko PJ, Posen GA, Burns KD: Daily hemofiltration with a simplified method of delivery. ASAIO J 49:426-429, 2003
88. Kubo S, Date H: Clinical usefulness of frequent short-time hemodiafiltration: trial for the effective removal of beta-2-microglobulin. Nephron 72:93-97, 1996
89. Maduell F, Navarro V, Torregrosa E, Rius A, Dicenta F, Cruz MC, Ferrero JA: Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration. Kidney Int 64:305-313, 2003
90. Moustapha A, Gupta A, Robinson K, Arheart K, Jacobsen DW, Schreiber MJ, Dennis VW: Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int 55:1470-1475, 1999
91. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Removal of the protein bound solute p-cresol by convective transport: a randomized cross-over study. Am J Kidney Dis 44:278-285, 2002
92. Kim DJ, Do JH, Huh W, Kim YG, Oh HY: Dissociation between clearances of small and middle molecules in incremental peritoneal dialysis. Perit Dial Int 21:462-466, 2001
93. Leypoldt JK, Cheung AK, Carroll CE, Stannard DC, Pereira BJ, Agodoa LY, Port FK: Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis 33:349-355, 1999
94. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T: Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 52:1096-1101, 1997
95. Woods HF, Nandakumar M: Improved outcome for haemodialysis patients treated with high-flux membranes. Nephrol Dial Transplant 15:36-42, 2000
96. Port FK, Wolfe RA, Hulbert-Shearon TE, Daugirdas JT, Agodoa LY, Jones C, Orzol SM, Held PJ: Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the USRDS Dialysis Morbidity and Mortality Study. Am J Kidney Dis 37:276-286, 2001
97. Falkenhagen D, Strobl W, Vogt G, Schrefl A, Linsberger I, Gerner FJ, Schoenhofen M: Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif Organs 23:83-86, 1999
98. Galli F, Benedetti S, Buoncristiani U, Piroddi M, Conte C, Canestrari F, Buoncristiani E, Floridi A: The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. Kidney Int 64:748-755, 2003
99. Niwa T, Asada H, Tsutsui S, Miyazaki T: Efficient removal of albumin-bound furancarboxylic acid by protein leaking hemodialysis. Am J Nephrol 15:463-467, 1995
100. Meyer T, Leeper E, Bartlett D, Depner T, Zhao Lit Y, Robertson C, Hostetter T: Increasing dialysate flow and dialyzer mass transfer area coefficient to increase the clearance of protein bound solutes. J Am Soc Nephrol 15:1927-1935, 2004
101. Dierkes J, Domrose U, Ambrosch A, Bosselmann HP, Neumann KH, Luley C: Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin Nephrol 51:108-15, 1999
102. Bellomo R, Tipping P, Boyce N: Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 21:522-527, 1993
103. Schiller LR, Santa Ana CA, Sheikh MS, Emmett M, Fordtran JS: Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 320:1110-1113, 1989
104. Jadoul M: Dialysis-related amyloidosis: importance of biocompatibility and age. Nephrol Dial Transplant 13(suppl):61-64, 1998
105. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T: Switch from conventional to high-flux membrane reduces risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 55:286-293, 1999
106. Niwa T, Takeda N, Maeda K, Shibata M, Tatematsu A: Accumulation of furancarboxylic acids in uremic serum as inhibitors of drug binding. Clin Chim Acta 173:127-138, 1988
107. Lesaffer G, De Smet R, Lameire N, Dhondt A, Duym P, Vanholder R: Intra-dialytic removal of protein bound uremic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 15:50-57, 2000
108. Niwa T, Yazawa T, Kodama T, Uehara Y, Maeda K, Yamada K: Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. Nephron 56:241-245, 1990
109. Lesaffer G, De Smet R, D'heuvaert T, Belpairea FM, Lameire N, Vanholder R: Kinetics of the protein bound, lipophilic, uremic toxin p-cresol in healthy rats. Life Sci 69:2237-2248, 2001
110. Lameire N, Vanholder R, De Smet R: Uremic toxins and peritoneal dialysis. Kidney Int Suppl 59:S292-S297, 2001
111. De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutter JH, Lameire NH: Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 10:846-853, 1999
112. Morgera S, Klonower D, Rocktaeschel J, Haase M, Priem F, Ziemer S, Wegner B, Gohl H, Neumayer HH. TNF-alpha elimination with high cut-off haemofilters: a feasible clinical modality for septic patients. Nephrol Dial Transplant 18:1361-69, 2003
113. Ash SR, Steczko J, Levy H, Blake DE, Carr DJ: Treatment of systemic inflammatory response syndrome by push-pull powdered sorbent pheresis: a phase 1 clinical trial. Ther Apher 5:497-505, 2001
114. Peter AT, Ash SR, Steczko J, Turek JJ, Blake DE, Carr DJ, Knab WR, Bosley RH: Push-pull sorbent-based pheresis treatment in an experimental canine endotoxemia model: preliminary report. Int J Artif Organs 22:177-188, 1999
115. Lornoy W, Becaus I, Billiouw JM, Sierens L, Van Malderen P, D'Haenens P: On-line haemodiafiltration. Remarkable removal of beta2-microglobulin. Long-term clinical observations. Nephrol Dial Transplant 15(suppl 1):S49-S54, 2000
116. Ding F, Ahrenholz P, Winkler RE, Ramlow W, Tiess M, Michelsen A, Patow W: Online hemodiafiltration versus acetate-free biofiltration: a prospective crossover study. Artif Organs 26:169-180, 2002
117. Gatchalian RA, Popli A, Ejaz AA, Leehey DJ, Kjellstrand CM, Ing TS: Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate. Am J Kidney Dis 36:1262-1266, 2000
118. Minutolo R, Bellizzi V, Cioffi M, Iodice C, Giannattasio P, Andreucci M, Terracciano V, Di Iorio BR, Conte G, De Nicola L: Postdialytic rebound of serum phosphorus: pathogenetic and clinical insights. J Am Soc Nephrol 13:1046-1054, 2002
119. Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W: A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. J Am Soc Nephrol 11:2344-2350, 2000
120. Pedrini LA, De Cristofaro V, Pagliari B, Sama F: Mixed predilution and postdilution online hemodiafiltration compared with the traditional infusion modes. Kidney Int 58:2155-2165, 2000
121. Wizemann V, Kulz M, Techert F, Nederlof B: Efficacy of haemodiafiltration. Nephrol Dial Transplant 16(suppl 4):S27-S30, 2001
122. Chanard J, Caudwell V, Valeire J, Vincent C, Randoux C, Wuillai A, Wynckel A: Kinetics of 131I-beta2 microglobulin in hemodialysis patients: assessment using total body counting. Artif Organs 22:574-580, 1998
123. Ahrenholz P, Winkler RE, Ramlow W, Tiess M, Mueller W: On-line hemodiafiltration with pre- and postdilution: a comparison of efficacy. Int J Artif Organs 20:81-90, 1997
124. Lornoy W, Becaus I, Billiouw JM, Sierens L, Van Malderen P: Remarkable removal of beta2-microglobulin by on-line hemodiafiltration. Am J Nephrol 18:105-108, 1998
125. Pedrini LA, De Cristofaro V: On-line mixed hemodiafiltration with a feedback for ultrafiltration control. Effect on middle molecule removal. Kidney Int 64:1505-1513, 2003
126. Lin CL, Yang CW, Chiang CC, Chang CT, Huang CC: Long-term on-line hemodiafiltration reduces predialysis beta-2-microglobulin levels in chronic hemodialysis patients. Blood Purif 19:301-307, 2001
127. Kerr PB, Argiles A, Flavier JL, Canaud B, Mion CM: Comparison of hemodialysis and hemodiafiltration: a long-term longitudinal study. Kidney Int 41:1035-1040, 1992
128. Maduell F, Navarro V, Cruz MC, Torregrosa E, Garcia D, Simon V, Ferrero JA: Osteocalcin and myoglobin removal in on-line hemodiafiltration versus low- and high-flux hemodialysis. Am J Kidney Dis 40:582-589, 2002
129. Schroder M, Riedel E, Beck W, Deppisch RM, Pommer W: Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes. Kidney Int 59:19-24, 2001
130. Bouman CS, van Olden RW, Stoutenbeek CP: Cytokine filtration and adsorption during pre- and postdilution hemofiltration in four different membranes. Blood Purif 16:261-268, 1998
131. Gil C, Lucas C, Possante C, Jorge C, Gomes F, Candeias M, Lages H, Arranhado E, Ferreira A: On-line haemo-diafiltration decreases serum TNFalpha levels in haemodialysis patients. Nephrol Dial Transplant 18:447-448, 2003
132. Goldfarb S, Golper TA: Proinflammatory cytokines and hemofiltration membranes. J Am Soc Nephrol 5:228-232, 1994
133. Wizemann V, Lotz C, Techert F, Uthoff S: On-line haemodiafiltration versus low-flux haemodialysis. A prospective randomized study. Nephrol Dial Transplant 15(suppl 1):S43-S48, 2000
134. Bonforte G, Grille P, Zerbi S, Surian M: Improvement of anemia in hemodialysis patients treated by hemodiafiltration with high-volume on-line-prepared substitution fluid. Blood Purif 20:357-363, 2002
135. Lin CL, Huang CC, Yu CC, Wu CH, Chang CT, Hsu HH, Hsu PY, Yang CW: Improved iron utilization and reduced erythropoietin resistance by on-line hemodiafiltration. Blood Purif 20:349-356, 2002
136. Gonella M, Pratesi G, Calabrese G, Vagelli G, Mazzotta A: Improvement of anemia in patients on chronic dialysis treated by hemodiafiltration. Blood Purif 7:186-191, 1989
137. Le Meur Y, Lorgeot V, Comte L, Szelag JC, Aldigier JC, Leroux-Robert C, Praloran V: Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kidney Dis 38:510-517, 2001
138. Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H: Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 17:809-813, 1993
139. Abe T, Abe T, Ageta S, Kakuta T, Suzuki N, Hirata H, Shouno M, Saio H, Akizawa T: A new method for removal of albumin binding uremic toxins: efficacy of an albumin-dialysate. Ther Apher 5:58-63, 2001
140. Khuroo M, Khuroo MS, Farahat K: Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl 10:1099-1106, 2004
141. Rifai K, Ernst T, Kretschmer U, Bahr MJ, Schneider A, Hafer C, Haller H, Manns MP, Fliser D: Prometheus - a new extracorporeal system for the treatment of liver failure. J Hepatol 39:984-990, 2003
142. Wratten ML, Sereni L, Tetta C: Hemolipodialysis attenuates oxidative stress and removes hydrophobic toxins. Artif Organs 24:685-690, 2000